Tonix Pharmaceuticals Holding Corp (LTS:0A4T)
$ 134.6 0 (0%) Market Cap: 17.80 Mil Enterprise Value: 12.04 Mil PE Ratio: 0 PB Ratio: 0.40 GF Score: 31/100

Tonix Pharmaceuticals Holding Corp At Investor Summit (Virtual) Transcript

Mar 29, 2023 / 01:00PM GMT
Release Date Price: $134.6
Gage Greeno
Ascent Conference - Moderator

Good morning, everyone, and thank you for tuning in to Investor Summit's March event. Joining us right now today is Jessica Morris, Chief Operating Officer at Tonix Pharmaceuticals. Jessica, I'm going to let you go ahead and get started.

Jessica Morris
Tonix Pharmaceuticals Holding Corp. - COO

Great. Thank you very much, Gage, and thank you for having Tonix as a presenter at the Investor Summit conference today. I am sharing my screen. Hopefully, everyone can see that. This next slide is just our forward-looking statements disclosure. I will be making forward-looking statements, and we are a public company. So, I would direct you to our SEC filings, including our 10-K that was recently filed.

Tonix is a clinical stage biopharmaceutical company, and our mission is to improve population health by inventing and developing new therapies as well as new vaccines. And we do this through not only our broad in-house capabilities, but also strategic collaborations to address important unmet needs in very large markets

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot